Vertex Pharmaceuticals Incorporated
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG000C1S2X2
VRTX
Vertex Pharmaceuticals Incorporated
GICS: -
·
Sector: Healthcare
·
Sub-Sector: Biotechnology
NAME
Vertex Pharmaceuticals Incorporated
ISIN
US92532F1003
TICKER
VRTX
MIC
XNAS
REUTERS
VRTX.OQ
BLOOMBERG
VRTX US
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Mon, 04.11.2024
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2024, and raised its full-year product revenue guidance to $10.8 billion to $10.9 billion.
“The third quarter marked another period of strong progress, with continued revenue growth and outstanding execution a...
Vertex Pharmaceuticals
Tue, 29.10.2024
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.
Dr. Reshma Kewalramani, Chief Executive Officer and President, will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 9:00 a.m. ET.
Stuart A...
Vertex Pharmaceuticals
Fri, 25.10.2024
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on multiple kidney diseases in its pipeline including IgA nephropathy (IgAN), primary membranous nephropathy (pMN), and APOL1-mediated kidney disease (AMKD). These updates demonstrate the transformative potential of Vertex’s investigational therapies in multiple serious kidn...
Vertex Pharmaceuticals
Fri, 18.10.2024
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain, at the annual meeting of the American Society of Anesthesiologists (ASA), taking place ...
Vertex Pharmaceuticals
Thu, 10.10.2024
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Ver...
Vertex Pharmaceuticals
Thu, 26.09.2024
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first accepted medical presentations of the Phase 3 data on the investigational once daily vanzacaftor/tezacaftor/deutivacaftor (“vanza triple”) — the potential next-in-class triple combination medicine — will take place at the North American Cystic Fibrosis Conference (NACFC)....
Vertex Pharmaceuticals
Thu, 22.08.2024
Vertex Pharmaceuticals
US92532F1003
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.
Dr. Reshma Kewalramani, Chief Executive Officer and President, and Charles Wagner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global He...
Vertex Pharmaceuticals
Information on product placements
